Huszár S, Chibale K, Singh V. The quest for the holy grail: new antitubercular chemical entities, targets and strategies. Drug Discov Today. 2020;25:772–80.

Article  PubMed  PubMed Central  Google Scholar 

Ejalonibu MA, Ogundare SA, Elrashedy AA, Ejalonibu MA, Lawal MM, Mhlongo NN, et al. Drug discovery for mycobacterium tuberculosis using structure-based computer-aided drug design approach. Int J Mol Sci. 2021;22: 13259.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022;20:685–701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe. 2023;4: e20. https://doi.org/10.1016/S2666-5247(22)00359-7.

Article  PubMed  Google Scholar 

Mishra SK, Tripathi G, Kishore N, Singh RK, Singh A, Tiwari VK. Drug development against tuberculosis: impact of alkaloids. Eur J Med Chem. 2017;137:504–44.

Article  CAS  PubMed  Google Scholar 

Huang Y, Ai L, Wang X, Sun Z, Wang F. Review and updates on the diagnosis of tuberculosis. J Clin Med. 2022;11:5286.

Article  PubMed  PubMed Central  Google Scholar 

Rabaan AA, Alhumaid S, Albayat H, Alsaeed M, Alofi FS, Al-Howaidi MH, et al. Promising antimycobacterial activities of flavonoids against Mycobacterium sp. drug targets: a comprehensive review. Molecules. 2022;27:5335.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tiberi S, Utjesanovic N, Galvin J, Centis R, D’Ambrosio L, van den Boom M, et al. Drug resistant TB–latest developments in epidemiology, diagnostics and management. Int J Infect Dis. 2022;124:S20–5.

Article  CAS  PubMed  Google Scholar 

Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629–61.

Article  CAS  PubMed  Google Scholar 

de la Torre BG, Albericio F. The pharmaceutical industry in 2019. An analysis of FDA drug approvals from the perspective of molecules. Molecules. 2020;25: 745.

Article  PubMed  PubMed Central  Google Scholar 

Mdluli K, Kaneko T, Upton A. The Tuberculosis drug discovery and development pipeline and emerging drug targets the recent accelerated approval for use in extensively drug-resistant and multidrug-resistant-tuberculosis (MDR-TB) of two first-in-class TB drugs. Cold Spring Harb Perspect Med. 2015;5: a021154.

Article  PubMed  PubMed Central  Google Scholar 

Cazzaniga G, Mori M, Chiarelli LR, Gelain A, Meneghetti F, Villa S. Natural products against key Mycobacterium tuberculosis enzymatic targets: emerging opportunities for drug discovery. Eur J Med Chem. 2021;224: 113732.

Article  CAS  PubMed  Google Scholar 

Agnivesh PK, Roy A, Sau S, Kumar S, Kalia NP. Advancements and challenges in tuberculosis drug discovery: a comprehensive overview. Microb Pathog. 2025;2025: 107074.

Article  Google Scholar 

Getahun M, Blumberg HM, Ameni G, Beyene D, Kempker RR. Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia. PLoS ONE. 2022;17: e0274426.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jadaun GPS, Agarwal C, Sharma H, Ahmed Z, Upadhyay P, Faujdar J, et al. Determination of ethambutol MICs for Mycobacterium tuberculosis and Mycobacterium avium isolates by resazurin microtitre assay. J Antimicrob Chemother. 2007;60:152–5.

Article  CAS  PubMed  Google Scholar 

Chakraborty S, Rhee KY. Tuberculosis drug development: History and evolution of the mechanism-based paradigm. Cold Spring Harb Perspect Med. 2015;5: a021147.

Article  PubMed  PubMed Central  Google Scholar 

Kumar G, Marutha C. Natural products and their analogues acting against Mycobacterium tuberculosis: a recent update. Drug Dev Res. 2023;84:779–804.

Article  CAS  PubMed  Google Scholar 

Maxwell A, Ghate V, Aranjani J, Lewis S. Breaking the barriers for the delivery of amikacin: challenges, strategies, and opportunities. Life Sci. 2021;284: 119883.

Article  CAS  PubMed  Google Scholar 

Koseki Y, Okamoto S. Studies on cross-resistance between capreomycin and certain other anti-mycobacterial agents. Jpn J Med Sci Biol. 1963;16:31–8.

Article  CAS  PubMed  Google Scholar 

Wu X, Shang Y, Ren W, Wang W, Wang Y, Xue Z, et al. Minimum inhibitory concentration of cycloserine against Mycobacterium tuberculosis using the MGIT 960 system and a proposed critical concentration. Int J Infect Dis. 2022;121:148–51.

Article  CAS  PubMed  Google Scholar 

Cohen KA, Stott KE, Munsamy V, Manson AL, Earl AM, Pym AS. Evidence for expanding the Role of Streptomycin in the management of drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;64:e00860-e920.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Igarashi M, Ishizaki Y, Takahashi Y. New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development. J Antibiot. 2018;71:15–25.

Article  CAS  Google Scholar 

Truax NJ, Romo D. Bridging the gap between natural product synthesis and drug discovery. Nat Prod Rep R Soc Chem. 2020;37:1436–53.

Article  CAS  Google Scholar 

Schetz JA. Structure-activity relationships: theory, uses and limitations. Ref Modul Biomed Sci. 2015. https://doi.org/10.1016/B978-0-12-801238-3.05329-0.

Article  Google Scholar 

Bandodkar B, Shandil RK, Bhat J, Balganesh TS. Two decades of tb drug discovery efforts-What have we learned? Appl Sci. 2020;10:5704.

Article  CAS  Google Scholar 

Swain SS, Sharma D, Hussain T, Pati S. Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2020;9:1651–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li F, Marwitz F, Rudolph D, Gauda W, Cohrs M, Neumann PR, et al. A comparative pharmacokinetics study of orally and intranasally administered 8-Nitro-1,3-benzothiazin-4-one (BTZ043) amorphous drug nanoparticles. ACS Pharmacol Transl Sci. 2024;7:4123–34.

Article  CAS  PubMed  Google Scholar 

Zhao H, Wang B, Fu L, Li G, Lu H, Liu Y, et al. Discovery of a conformationally constrained oxazolidinone with improved safety and efficacy profiles for the treatment of multidrug-resistant tuberculosis. J Med Chem. 2020;63:9316–39.

Article  CAS  PubMed  Google Scholar 

Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. Int J Infect Dis. 2021;113:S96-99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao H, Lu Y, Sheng L, Yuan Z, Wang B, Wang W, et al. Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant tuberculosis. ACS Med Chem Lett. 2017;8:533–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jahng Y. Progress in the studies on tryptanthrin, an alkaloid of history. Arch Pharm Res. 2013;36:517–35.

Article